{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:27:22Z","timestamp":1722414442340},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T00:00:00Z","timestamp":1356566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s12032-012-0351-4","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T11:15:29Z","timestamp":1356520529000},"source":"Crossref","is-referenced-by-count":28,"title":["Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Mei","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-hui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-liang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-gong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-kai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,27]]},"reference":[{"key":"351_CR1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341\u20133.","journal-title":"Lancet Oncol"},{"key":"351_CR2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0889-8588(03)00119-9","volume":"17","author":"CE Dearden","year":"2003","unstructured":"Dearden CE, Foss FM. Peripheral T-cell lymphomas: diagnosis and management. Hematol Oncol Clin N Am. 2003;17:1351\u201366.","journal-title":"Hematol Oncol Clin N Am"},{"key":"351_CR3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"351_CR4","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008."},{"key":"351_CR5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/10428190290016926","volume":"43","author":"M Reiser","year":"2002","unstructured":"Reiser M, Josting A, Soltani M, et al. T-cell non-Hodgkin\u2019slymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002;43:805\u201311.","journal-title":"Leuk Lymphoma"},{"key":"351_CR6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11864-004-0020-8","volume":"5","author":"AM Evens","year":"2004","unstructured":"Evens AM, Gartenshaus RB. Treatment of T-cell non-Hodgkin\u2019s lymphoma. Curr Treat Opt Oncol. 2004;5:289\u2013303.","journal-title":"Curr Treat Opt Oncol"},{"key":"351_CR7","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1080\/1042819021000039983","volume":"43","author":"C Besson","year":"2002","unstructured":"Besson C, Panelatti G, Delaunay C, et al. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma. 2002;43:2275\u20139.","journal-title":"Leuk Lymphoma"},{"key":"351_CR8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T Kewalramani","year":"2006","unstructured":"Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134:202\u20137.","journal-title":"Br J Haematol"},{"key":"351_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2008.10.011","volume":"71","author":"J Rodriguez","year":"2009","unstructured":"Rodriguez J, Gutierrez A, Martinez-Delgado B, et al. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol. 2009;71:181\u201398.","journal-title":"Crit Rev Oncol Hematol"},{"key":"351_CR10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21:860\u20133.","journal-title":"Ann Oncol"},{"key":"351_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica. 2007;92:271\u20132.","journal-title":"Haematologica"},{"key":"351_CR12","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood.V116.21.2829.2829","volume":"116","author":"G Corazzelli","year":"2010","unstructured":"Corazzelli G, Frigeri F, Marcacci G, et al. Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell\/NK lymphomas: a phase II trial [abstract]. Blood. 2010;116:2829.","journal-title":"Blood"},{"key":"351_CR13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"351_CR14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI sponsored International Working Group. J Clin Oncol. 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"351_CR15","first-page":"3","volume":"23","author":"W Plunkett","year":"1996","unstructured":"Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23:3\u201315.","journal-title":"Semin Oncol"},{"key":"351_CR16","first-page":"4024","volume":"48","author":"V Heinemann","year":"1988","unstructured":"Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2\u2032,2\u2032-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine. Cancer Res. 1988;48:4024\u201331.","journal-title":"Cancer Res"},{"issue":"2 Suppl 7","key":"351_CR17","first-page":"S7-2","volume":"24","author":"AM Storniolo","year":"1997","unstructured":"Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol. 1997;24(2 Suppl 7):S7-2\u20137.","journal-title":"Semin Oncol"},{"key":"351_CR18","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","volume":"18","author":"PL Zinzani","year":"2000","unstructured":"Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603\u20136.","journal-title":"J Clin Oncol"},{"key":"351_CR19","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","volume":"104","author":"E Marchi","year":"2005","unstructured":"Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104:2437\u201341.","journal-title":"Cancer"},{"key":"351_CR20","first-page":"521","volume":"2","author":"AM Bergman","year":"1996","unstructured":"Bergman AM, Ruiz van Haparen V, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521\u201330.","journal-title":"Clin Cancer Res"},{"key":"351_CR21","first-page":"47","volume":"22","author":"K Csoka","year":"1995","unstructured":"Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995;22:47\u201353.","journal-title":"Semin Oncol"},{"key":"351_CR22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","volume":"17","author":"F Cardenal","year":"1999","unstructured":"Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine\u2013cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12\u20138.","journal-title":"J Clin Oncol"},{"key":"351_CR23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92\u20138.","journal-title":"N Engl J Med"},{"key":"351_CR24","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377.","journal-title":"J Clin Oncol"},{"key":"351_CR25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101:1835\u201342.","journal-title":"Cancer"},{"issue":"Suppl 4","key":"351_CR26","first-page":"111","volume":"22","author":"D Mahadevan","year":"2011","unstructured":"Mahadevan D, Unger JM, Persky DO, et al. Phase II trial of cisplatin plus etoposide plus gemcitabine plus solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350) [abstract]. Ann Oncol. 2011;22(Suppl 4):111.","journal-title":"Ann Oncol"},{"key":"351_CR27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1385\/MO:20:1:13","volume":"20","author":"A Aviles","year":"2003","unstructured":"Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK\/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol. 2003;20:13\u20137.","journal-title":"Med Oncol"},{"key":"351_CR28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/10428190600562823","volume":"47","author":"KW Lee","year":"2006","unstructured":"Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy\u00a0\u00b1\u00a0radiotherapy is active in stage I\/II extranodal NK\/T-cell lymphoma. Leuk Lymphoma. 2006;47:1274\u201382.","journal-title":"Leuk Lymphoma"},{"key":"351_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/annonc\/mdn551","volume":"20","author":"BS Kim","year":"2009","unstructured":"Kim BS, Kim DW, Im SA, et al. Effective second-line chemotherapy for extranodal NK\/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol. 2009;20:121\u20138.","journal-title":"Ann Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-012-0351-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0351-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T11:37:24Z","timestamp":1595158644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-012-0351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s12032-012-0351-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,27]]},"article-number":"351"}}